Recruiting
HER3-DXd
Phase 1 Phase 2 Tumor-agnostic
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Trial #: NCT06941272
Recruiting
I-DXd
Phase 3 Genitourinary Cancers
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Trial #: NCT06925737
Recruiting
R-DXd
Phase 2 Gastric Cancer
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
Trial #: NCT06864169
Recruiting
I-DXd
Phase 1 Phase 2 Genitourinary Cancers
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Trial #: NCT06863272
Recruiting
R-DXd
Phase 1 Phase 2 Gynecologic Cancers
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Trial #: NCT06843447
Recruiting
HER3-DXd
Phase 2 Breast Cancer
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Trial #: NCT06797635
Recruiting
HER3-DXd
Phase 1 Phase 2 Breast Cancer
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Trial #: NCT06686394
Recruiting
HER3-DXd
Phase 1 Phase 2 Gastric Cancer
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Trial #: NCT06596694
Recruiting
I-DXd
Phase 1 Phase 2 Esophageal Cancer
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Trial #: NCT06780111
Recruiting
T-DXd
Breast Cancer
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
Trial #: NCT05573893
Pages: 1  2  3  4  5  6  7  

The content contained is taken is taken directly from public registry ClinicalTrials.gov and has not been edited.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.